Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study

被引：2
|
作者：
Chapman, Kenneth R.
Vogelmeier, Claus F.
FowlerTaylor, Angel
Ayers, Tim
Thach, Chau
Shrinivasan, Anupama
Fogel, Robert
Patalano, Francesco
Banerji, Donald
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2016年 / 48卷
关键词：
Bronchodilators; COPD; -; exacerbations; Treatments;
D O I：
10.1183/13993003.congress-2016.PA296
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA296
引用
收藏
页数：2
相关论文
共 50 条
  • [1] EFFECT OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) VS SALMETEROL/FLUTICASONE (SFC) ON MODERATE OR SEVERE COPD EXACERBATIONS AND LUNG FUNCTION BASED ON BASELINE BLOOD EOSINOPHIL COUNTS: RESULTS FROM THE FLAME STUDY
    Chapman, Kenneth R.
    Vogelmeier, Claus F.
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Shrinivasan, Anupama
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    RESPIROLOGY, 2017, 22 : 85 - 85
  • [2] SAFETY OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) COMPARED WITH SALMETEROL/FLUTICASONE (SFC) IN MODERATE-TO-VERY SEVERE COPD PATIENTS WITH PRIOR EXACERBATIONS: RESULTS FROM THE FLAME STUDY
    Wedzicha, J.
    Vestbo, J.
    Larbig, M.
    Fogel, R.
    Thach, C.
    Patalano, F.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 181 - 181
  • [3] INDACATEROL/GLYCOPYRRONIUM (IND/GLY) IS SUPERIOR TO SALMETEROL/FLUTICASONE (SFC) IN ASIAN PATIENTS WITH MODERATE-TO-VERY SEVERE COPD AT A HIGH RISK OF EXACERBATIONS: FLAME STUDY RESULTS
    Wedzicha, J. A.
    Zhong, N.
    Ichinose, M.
    Larbig, M.
    Humphries, M.
    Fogel, R.
    Thach, C.
    Patalano, F.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 180 - 180
  • [4] Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study
    Chapman, Kenneth R.
    Roche, Nicolas
    Ayers, Tim
    FowlerTaylor, Angel
    Thach, Chau
    Ahlers, Norbert
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [5] Indacaterol/glycopyrronium (IND/GLY) reduces days with COPD exacerbation vs salmeterol/fluticasone (SFC) independent of PRO tool: results of the FLAME study
    Wedzicha, Jadwiga
    Chapman, Kenneth R.
    Frent, Stefan-Marian
    Shen, Steven
    Patalano, Francesco
    Larbig, Michael
    Fogel, Robert
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [6] Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
    Roche, Nicolas
    Olsson, Petter
    Vestbo, Jorgen
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Clerkin, Karyn
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [7] Respiratory safety profile of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC): results from the FLAME study
    Wedzicha, Jadwiga
    Vogelmeier, Claus F.
    Ayers, Tim
    Olsson, Petter
    Patalano, Francesco
    Thach, Chau
    Fogel, Robert
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [8] Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study
    Wedzicha, Jadwiga
    Chapman, Kenneth
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Olsson, Petter
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [9] EFFICACY OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) VERSUS SALMETEROL/FLUTICASONE (SFC) ON EXACERBATIONS AND HEALTH STATUS IN GOLD GROUP D COPD PATIENTS: THE FLAME STUDY
    Larbig, Michael
    Vogelmeier, Claus F.
    Roche, Nicolas
    Ayers, Tim
    FowlerTaylor, Angel
    Thach, Chau
    Shrinivasan, Anupama
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    RESPIROLOGY, 2017, 22 : 131 - 131
  • [10] Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
    Larbig, Paul Michael
    Vogelmeier, Claus
    Roche, Nicolas
    Ayers, Tim
    FowlerTaylor, Angel
    Thach, Chau
    Shrinivasan, Anupama
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12345